EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 990 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR How Living in Service to Others Helped Me Cope During Cancer March 9, 2023 Axicabtagene Ciloleucel Results in High Response Rates and Durable Remissions as... October 5, 2023 FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular... February 11, 2021 New on NCI Websites for July 2019 July 2, 2019 Load more HOT NEWS Two Women With Terminal Breast Cancer Started A Podcast That’s Unflinchingly... Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO... Five Questions With…Jae. Wawa Employee Saves Life Of Customer Who Stopped Breathing After A...
